SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Estey E, Keating M, McCredie K, Bodey G, Freireich E. Causes of initial remission failure in patients with acute myelogenous leukemia. Blood. 1982; 60: 309315.
  • 2
    Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996; 10: 600608.
  • 3
    Mattiuzzi G, Pierce S, Faderl S, Cortes J, Koller C, Estey E. Causes of pneumonia (PN) in patients (PTS) with acute myelogenous leukemia (AML) or– myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). [abstract 1399]. Presented at the 42nd American Society of Hematology Meeting, San Francisco, California, December 2000 Blood, 2000; 96: 11a.
  • 4
    Boogaerts MA, Maertens J, Van der Geest R, et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by 14-day administration of itraconazole oral solution in patients with hematologic malignancies. Antimicrob Agents Chemother. 2001; 45: 981985.
  • 5
    Zhou H, Goldman M, Wu J, et al. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol. 1998; 38: 593602.
  • 6
    Asicoglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34: 714.
  • 7
    Huijgens PC, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in hemato-oncology. J Clin Pathol. 1999; 52: 376380.
  • 8
    Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother. 2000; 44: 18871893.
  • 9
    Menichetti F, Del Favero A, Martino P, et al and the GIMENA Infection Program. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis. 1999; 28: 250255.
  • 10
    Boogaerts M, Maertens J, van Hoof A, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother. 2002; 48: 97103.
  • 11
    Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW on behalf of the U.K. Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol. 1999; 105: 901911.
  • 12
    Mattiuzzi G, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003; 97: 450456.
  • 13
    Estey E, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia. 1989; 3: 257263.
  • 14
    Estey E. Prognostic factors in cancer clinical trials. Clin Cancer Res. 1997; 3: 25912593.
  • 15
    National Cancer Institute common toxicity criteria–version 1. Available from URL: http://www.accessdata.fda.gov/scripts/cder/onctools/toxicity.cfmhttp://ctep.cancer.gov/reporting/ctc.html [accessed April 2000].